Author:
Wang Cheng,Zhao Peizhen,Weideman Ann Marie,Xu Wenqian,Ong Jason J.,Jamil Muhammad S.,Yang Bin,Tucker Joseph D.
Abstract
Abstract
Background
HCV self-testing (HCVST) may be an effective strategy to address low rates of HCV test uptake among men who have sex with men (MSM). We evaluated the effectiveness and cost of providing HCVST to increase HCV test uptake among MSM in China.
Methods
Two parallel, unmasked, individual-level randomized controlled trials were conducted. HIV-negative MSM and MSM living with HIV were enrolled from 22 cities in China. Men in both trials were randomly assigned (1:1) into standard-of-care (SOC) or HCVST arms. The primary outcome was the proportion of participants who tested for HCV during the trial period. Intervention effects were estimated using multiply imputed data in the main analysis. Costs were measured using a micro-costing approach.
Results
A total of 84 men who were HIV-negative (trial 1) and 84 men living with HIV were enrolled (trial 2). Overall, the proportion of individuals who underwent HCV testing during the trial period was higher in the HCVST arm compared to SOC in trial 1 (estimated risk difference (RD): 71.1%, 95% CI: 54.6 to 87.7%) and trial 2 (estimated RD: 62.9%, 95% CI: 45.7 to 80.1%). Over half (58.6%, 34/58) of HCV self-testers reported the self-test was their first HCV test. The cost per person tested in trial 1 was $654.52 for SOC and $49.83 for HCVST, and in trial 2 was $438.67 for SOC and $53.33 for HCVST.
Conclusions
Compared to the standard of care, providing HCVST significantly increased the proportion of MSM testing for HCV in China, and was cheaper per person tested.
Trial registration
Chinese Clinical Trial Registry. Registration number: ChiCTR2100048379.
Funder
Natural Science Foundation of Guangdong Province of China
Publisher
Springer Science and Business Media LLC
Reference44 articles.
1. World Health Organization (WHO). Progress report on access to hepatitis C treatment. https://www.who.int/hepatitis/publications/hep-c-access-report-2018/en/.
2. World Health Organization (WHO). Global health sector strategy on viral hepatitis 2016–2021. https://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/.
3. Zhang M, Wu R, Xu H, Uhanova J, Gish R, Wen X, Jin Q, Gerald MY, Nguyen M, Gao Y. Changing incidence of reported viral hepatitis in China from 2004 to 2016: an observational study. BMJ Open. 2019;9(8):e028248.
4. Liu CR, Li X, Chan PL, Zhuang H, Jia JD, Wang X, Lo YR, Walsh N. Prevalence of hepatitis C virus infection among key populations in China: a systematic review. Int J Infect Dis. 2019;80:16–27.
5. Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review. Ann Intern Med. 2017;166(9):637–48.